124 related articles for article (PubMed ID: 15676040)
1. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.
Jullien V; Tréluyer JM; Chappuy H; Dimet J; Rey E; Dupin N; Salmon D; Pons G; Urien S
Br J Clin Pharmacol; 2005 Feb; 59(2):183-8. PubMed ID: 15676040
[TBL] [Abstract][Full Text] [Related]
2. Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis.
Jullien V; Urien S; Chappuy H; Dimet J; Rey E; Pons G; Blanche S; Tréluyer JM
J Clin Pharmacol; 2005 Mar; 45(3):257-64. PubMed ID: 15703361
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
Jullien V; Tréluyer JM; Rey E; Jaffray P; Krivine A; Moachon L; Lillo-Le Louet A; Lescoat A; Dupin N; Salmon D; Pons G; Urien S
Antimicrob Agents Chemother; 2005 Aug; 49(8):3361-6. PubMed ID: 16048948
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
Zhao W; Cella M; Della Pasqua O; Burger D; Jacqz-Aigrain E;
Br J Clin Pharmacol; 2012 Apr; 73(4):641-50. PubMed ID: 21988586
[TBL] [Abstract][Full Text] [Related]
5. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.
Capparelli EV; Letendre SL; Ellis RJ; Patel P; Holland D; McCutchan JA
Antimicrob Agents Chemother; 2005 Jun; 49(6):2504-6. PubMed ID: 15917556
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus-infected children in relation to treatment outcomes.
Archary M; Mcllleron H; Bobat R; LaRussa P; Sibaya T; Wiesner L; Hennig S
Br J Clin Pharmacol; 2019 Sep; 85(9):2066-2075. PubMed ID: 31141195
[TBL] [Abstract][Full Text] [Related]
8. Impact of pregnancy on abacavir pharmacokinetics.
Best BM; Mirochnick M; Capparelli EV; Stek A; Burchett SK; Holland DT; Read JS; Smith E; Hu C; Spector SA; Connor JD;
AIDS; 2006 Feb; 20(4):553-60. PubMed ID: 16470119
[TBL] [Abstract][Full Text] [Related]
9. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S
Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function.
Izzedine H; Launay-Vacher V; Aymard G; Legrand M; Deray G
Nephron; 2001 Sep; 89(1):62-7. PubMed ID: 11528234
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
[TBL] [Abstract][Full Text] [Related]
12. Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis.
Jullien V; Raïs A; Urien S; Dimet J; Delaugerre C; Bouillon-Pichault M; Rey E; Pons G; Blanche S; Tréluyer JM
Br J Clin Pharmacol; 2007 Jul; 64(1):105-9. PubMed ID: 17324223
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
Kappelhoff BS; Huitema AD; Yalvaç Z; Prins JM; Mulder JW; Meenhorst PL; Beijnen JH
Clin Pharmacokinet; 2005; 44(8):849-61. PubMed ID: 16029069
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of abacavir in infants, toddlers and children.
Zhao W; Piana C; Danhof M; Burger D; Della Pasqua O; Jacqz-Aigrain E
Br J Clin Pharmacol; 2013 Jun; 75(6):1525-35. PubMed ID: 23126277
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
Kappelhoff BS; Huitema AD; Crommentuyn KM; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
Br J Clin Pharmacol; 2005 Feb; 59(2):174-82. PubMed ID: 15676039
[TBL] [Abstract][Full Text] [Related]
16. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years.
Jullien V; Urien S; Hirt D; Delaugerre C; Rey E; Teglas JP; Vaz P; Rouzioux C; Chaix ML; Macassa E; Firtion G; Pons G; Blanche S; Tréluyer JM
Antimicrob Agents Chemother; 2006 Nov; 50(11):3548-55. PubMed ID: 16940058
[TBL] [Abstract][Full Text] [Related]
17. A review of the pharmacokinetics of abacavir.
Yuen GJ; Weller S; Pakes GE
Clin Pharmacokinet; 2008; 47(6):351-71. PubMed ID: 18479171
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.
McDowell JA; Chittick GE; Ravitch JR; Polk RE; Kerkering TM; Stein DS
Antimicrob Agents Chemother; 1999 Dec; 43(12):2855-61. PubMed ID: 10582871
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.
Weller S; Radomski KM; Lou Y; Stein DS
Antimicrob Agents Chemother; 2000 Aug; 44(8):2052-60. PubMed ID: 10898675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
